Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.
Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).
Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.
Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.
Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178